Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021
As Israeli Firm Publishes Full-Year Results
Executive Summary
Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.
You may also be interested in...
Teva Debuts US Azopt Rival
Teva has launched the first and so far only US generic version of Novartis’ Azopt treatment for ocular hypertension, with the brinzolamide 1% solution having been developed and manufactured by Indoco Remedies.
Stock Watch: The Pandemic – Where Generics Failed To Reign
If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.
Teva Takes On Amneal With Second US NuvaRing Rival
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.